Abstract
A novel and efficient synthesis of 4-substituted 2-oxazolidinones is described; the synthesis utilizes Sharpless asymmetric dihydroxylation (AD) of appropriately substituted O-allylcarbamates and intramolecular cyclisation as key steps.
Keywords: chiral, substituted -oxazolidinones, asymmetric dihydroxylation, intramolecular cyclisation
Letters in Organic Chemistry
Title: A Simple Asymmetric Synthesis of 4-Substituted-2-Oxazolidinones
Volume: 2 Issue: 7
Author(s): V. J. Sattigeri, A. S.S.V. Srinivas, A. Soni, J. M. Khanna and A. Mehta
Affiliation:
Keywords: chiral, substituted -oxazolidinones, asymmetric dihydroxylation, intramolecular cyclisation
Abstract: A novel and efficient synthesis of 4-substituted 2-oxazolidinones is described; the synthesis utilizes Sharpless asymmetric dihydroxylation (AD) of appropriately substituted O-allylcarbamates and intramolecular cyclisation as key steps.
Export Options
About this article
Cite this article as:
Sattigeri J. V., Srinivas S.S.V. A., Soni A., Khanna M. J. and Mehta A., A Simple Asymmetric Synthesis of 4-Substituted-2-Oxazolidinones, Letters in Organic Chemistry 2005; 2 (7) . https://dx.doi.org/10.2174/157017805774296876
DOI https://dx.doi.org/10.2174/157017805774296876 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent
Potential Therapeutic Approaches for COVID-19
Endocrine, Metabolic & Immune Disorders - Drug Targets In Silico Technology for Identification of Potentially Toxic Compounds in Drug Discovery
Current Computer-Aided Drug Design Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry Nanoparticle-Protein Conjugates for Nanomedicine Applications: Design and Engineering at the Nano-Bio Interface
Recent Patents on Nanomedicine Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Current Topics in Medicinal Chemistry Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Effectiveness of Azithromycin as Add-on Therapy in COVID-19 Management
Mini-Reviews in Medicinal Chemistry Preface
Infectious Disorders - Drug Targets Recent Studies on Design and Development of Drugs Against Alzheimer’s Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents
Current Topics in Medicinal Chemistry Glucocorticoid Receptor Antagonists
Current Topics in Medicinal Chemistry Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Current Topics in Medicinal Chemistry In Silico Methods for Predicting Ligand Binding Determinants of Cytochromes P450
Current Topics in Medicinal Chemistry Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors
Mini-Reviews in Medicinal Chemistry Host-Pathogen Interactions Made Transparent with the Zebrafish Model
Current Drug Targets Targeted Therapy in Advanced Gastric Carcinoma: The Future is Beginning
Current Medicinal Chemistry Cysteinyl Leukotriene Receptor Antagonists and Thromboxane Synthase Inhibitors: New Targets to Treat Asthma
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry Pharmaceutical and Biomedical Potential of PEGylated Dendrimers
Current Pharmaceutical Design Pixuvri<sup>®</sup> (Pixantrone Dimaleate, BBR 2778): From Lab to Market
Current Organic Chemistry Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design